They actually had a bit more cash as of Q4 but they'll likely burn 10-15m in Q1.
The loan was for 125m they borrowed the first tranche of 80 mil and the other 45 mil is contingent on Omidria sales/market cap. I don't see EU partnership for Omidria bringing much (if anything) and would be disappointing to see them dilute their 721 interest. GPCR's haven't found a partner in years so I am speculating equity offering based on 2 PR's one after the other that aren't new which result in big stock movement.
They said $55M was run rate (based on weekly scripts on one of their calls), if its only that for '17 I'd be very disappointed.
Don't get me wrong I do like the pipeline MASP programs, GPCR's (though they have been slow in developing compounds to target them) particularly targeting GPR174 which is in animal studies.
News 
Market Data 
Discover 
